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The current treatment for metastatic gastric cancer (MGC) consists of cisplatin and/or fluorouracil (5-FU) based combination
chemotherapy, but cisplatin-based regimens are associated with considerable toxicity. We evaluated the efficacy and safety of a
noncisplatin-, non-5-FU-containing regimen, docetaxel/irinotecan in MGC. Chemo-naive patients with MGC received docetaxel
(30mgm
 2) and irinotecan (70mgm
 2) on days 1 and 8 every 3 weeks. The 48 eligible patients (median age 56 years) received a
median of four cycles of docetaxel/irinotecan (range 1–18). Of the 46 patients in whom efficacy could be evaluated, 21 showed a
partial response (response rate¼45.7%; 95% confidence interval (CI) 31.3–60.1%). At a median follow-up of 15.0 months, the
median time to progression was 4.5 months (95% CI 3.8–5.2 months) and overall survival was 8.2 months (95% CI, 5.8–10.6
months). Grade 3/4 neutropenia developed in 57.4% of patients, and febrile neutropenia/neutropenic infection in 19.1%.
Nonhaematological toxicities were moderate; grade 3/4 diarrhoea occurred in 19.1% of patients, however, was manageable by a
dose reduction. There was one possible treatment-related death. In conclusion, weekly docetaxel/irinotecan is a promising outpatient
regimen in MGC, with appropriate dose modification.
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Despite its decreasing incidence over the past few decades, gastric
cancer remains one of the major causes of cancer deaths worldwide
(Jemal et al, 2004) and is the most prevalent malignancy in Korea,
constituting 24% of all solid tumours in males and 15% in females
(Shin et al, 2004). Systemic chemotherapy is often used in patients
with locally advanced or metastatic gastric cancer (MGC), but
results of most combination regimens have been unsatisfactory,
with median survival times of 6–9 months (Webb et al, 1997;
Vanhoefer et al, 2000; Ohtsu et al, 2003). To data, the combination
chemotherapies most commonly used have been based on
fluorouracil (5-FU) and/or cisplatin, with 5-FU/cisplatin (FP) and
epirubicin/cisplatin/5-FU currently regarded as reference treat-
ment. However, cisplatin-based chemotherapy is associated with
an unfavuorable toxicity profile, including severe emesis, neuro-
toxicity and nephrotoxicity. In addition, the need for intense
intravenous (i.v.) hydration complicates the administration of this
drug. Therefore, there is a need to develop active but less toxic
chemotherapy regimens, which include new active compounds.
Docetaxel, which inhibits microtubule depolymerization, has
been widely used in the treatment of MGC, with several phase II
trials showing that this drug, as a single agent, induces response
rates of 16–24% (Sulkes et al, 1994; Bang et al, 2002). Moreover,
when combined with cisplatin, docetaxel has produced response
rates of 33–56% (Roth et al, 2000; Kettner et al, 2001; Ridwelski
et al, 2001; Ajani et al, 2005).
Irinotecan, which inhibits topoisomerase I, thereby disrupting
DNA replication, is a cytotoxic agent with promising activity. In
MGC, irinotecan monotherapy has shown response rates of 20–
23% (Futatsuki et al, 1994; Kohne et al, 2003) and irinotecan plus
cisplatin has resulted in response rates of 32–58% (Ajani et al,
2002; Lim et al, 2003; Pozzo et al, 2004).
Given the activity of docetaxel and irinotecan in MGC and the
different mechanisms of the two drugs, we designed a phase II trial
to examine the efficacy and toxicity of this new combination in
patients with MGC. As previous study of every-3-weeks docetaxel/
irinotecan in the chemo-naı ¨ve patients with advanced gastric
cancer showed considerable toxicities, especially grade 3/4
neutrpenia (85.4%) and febrile neutropenia/neutropenic infection
(41.4%) (Hawkins et al, 2003), and both drugs are myelosuppres-
sive, we administered each of these drugs once per week.
PATIENTS AND METHODS
Patients
Patients eligible for this trial were those aged over 18 years old with
histologically proven gastric adenocarcinoma, metastatic disease,
unidimensionally measurable disease, no prior chemotherapy
including adjuvant chemotherapy, Eastern Cooperative Oncology
Group (ECOG) performance status 0–2, and adequate baseline
hematological function (absolute neutrophil count (ANC)X1.
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9l
 1, platelet count X100 10
9l
 1), hepatic function (serum
aspartate aminotransferase and alanine aminotransferase p2.5 
the upper normal limit (UNL), serum bilirubin pUNL) and renal
function (serum creatinine pUNL).
Patients were excluded if they had a history of other
malignancies within the previous 3 years or pre-existing
peripheral neuropathy of grade X2 on the basis of the
National Cancer Institute Common Toxicity Criteria (NCI CTC)
(version 2.0). Written informed consent was obtained for
all patients, and the institutional review board approved the
protocol.
Treatment
Docetaxel (30mgm
 2) was administered as a 1-h i.v. infusion and
irinotecan (70mgm
 2) as a 90-min i.v. infusion on days 1 and 8 of
each 3-week cycle. Oral dexamethasone (8mg twice daily for six
doses, starting 24h before docetaxel) and parenteral pheniramine ma-
leate (45.5mg) were administered prophylactically. Prophylactic
administration of granulocyte-colony stimulating factor (G-CSF)
was not allowed. The next chemotherapy cycle was delayed if
ANC fell below 1.5 10
9l
 1, the platelet count below 100 10
9l
 1
or if patient experienced any other nonhaematological toxicity
excluding alopecia greater than grade 1. Doses of docetaxel and
irinotecan were reduced by 20% in subsequent cycles if patients
experienced grade 3 or 4 neutropenia with fever, grade 4
thrombocytopenia, or any grade X3 nonhaematological toxicity.
The dose of docetaxel was reduced by 20% in subsequent cycles if
patients experienced grade 2 or 3 neurologic toxicity or recurrent
fluid retention. The dose of irinotecan was reduced by 20 and 40%
in patients experiencing grade 2 diarrhoea and 3 or 4 diarrhoea,
respectively. Chemotherapy was administered on an outpatient
basis and continued until disease progression or unacceptable
toxicity developed.
Assessment of efficacy and toxicity
During the first two cycles, complete blood cell count and blood
chemistry was performed weekly. In subsequent chemotherapy
cycles, these tests were performed on days 1 and 8. A computed
tomography (CT) scan was performed every three cycles to
evaluate response to treatment. Complete response (CR), partial
response (PR), stable disease (SD) and progressive disease (PD)
were defined according to the response evaluation criteria in
solid tumour (RECIST) (Therasse et al, 2000). Responses were
confirmed by an expert independent radiologist. Time to
progression (TTP) was calculated from the date of first
chemotherapy cycle to the date of disease progression, death from
any cause, or last follow-up. Overall survival (OS) was calculated
from the date of first chemotherapy cycle to the date of death from
any cause or last follow-up. Toxicity was assessed before drug
dosing using the NCI CTC (version 2.0).
Statistical analysis
The primary end point of this study was response rate. Secondary
end points were TTP, OS and safety. The optimal Simon two-stage
design was used to determine the sample size (Simon, 1989). An
interim analysis was carried out when the first 15 assessable
patients had been recruited. If there were four or fewer responses,
the study was to be terminated. Otherwise, accrual was to be
continued to a total of 46 patients. If there were more than 18
responses among 46 patients, the treatment was considered
sufficiently active with a significance level of 5% and power of
80%. TTP and OS were analysed according to the Kaplan–Meier
method and updated to 30 August 2005.
RESULTS
Patient characteristics
From December 2003 to September 2004, 49 patients were enrolled
in this study, 29 (59.2%) males and 20 (40.8%) females, of median
age 56 years (range 29–72 years). Most of the patients (98.0%) had
ECOG PS 0-1, and 26 (53.1%) had multiple metastases involving
two or more organ systems. Metastatic sites were in the abdominal
lymph nodes (51.0%), peritoneum (49.0%), liver (36.7%), ovary
(12.2%) and others (34.7%) (Table 1). All patients had metastatic
disease at diagnosis and two of them received palliative
gastrectomy before the chemotherapy.
Efficacy
Of the 49 patients, 46 could be evaluated for response, whereas one
was ineligible because of a previous history of cervical cancer and
two were lost to follow-up prior to receiving three cycles of
chemotherapy. According to the independent review panel, 21
patients (45.7%) achieved confirmed PR, 15 (32.6%) had SD and 10
(21.7%) had PD. Thus, the overall response rate was 45.7% (95%
confidence interval (CI) 31.3–60.1%) (Table 2). All objective
responses were confirmed by follow-up CT at least 4 weeks after
the initial documentation of PR. The median duration of response
was 4.8 months (range 1.8–11.5þ months). The median follow-up
time was 15.0 months (range 11.6–21.0 months), during which the
median TTP was 4.5 months (95% CI 3.8-5.2 months) (Figure 1)
and the median OS was 8.2 months (95% CI 5.8–10.6 months)
Table 1 Patient characteristics
Characteristics Number of patients (%)
Number of entered patients 49
Number of eligible patients 48
Age (years)
Median 56
Range 29–72
Gender
Male 29 (59.2)
Female 20 (40.8)
ECOG performance status
0 3 (6.1)
1 45 (91.9)
2 1 (2.0)
Hiostology
Adenocarcinoma, well differentiated 2 (4.1)
Adenocarcinoma, moderately differentiated 14 (28.6)
Adenocarcinoma, poorly differentiated 17 (34.7)
Signet ring cell carcinoma 16 (32.6)
Metastatic organ sites
Abdominal lymph node 25 (51.0)
Peritoneum 24 (49.0)
Liver 18 (36.7)
Ovary 6 (12.2)
Others
a 17 (34.7)
Number of metastatic organ sites
1 23 (46.9)
2 14 (28.6)
X3 12 (24.5)
ECOG¼Eastern Cooperative Oncology Group.
aCervical lymph node, lung, bone,
adrenal gland, uterus, gall bladder, pancreas.
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39.6%).
Treatment delivered
A total of 250 cycles were administered, with a median of 4 per
patient (range 1–18). Treatment was delayed for a median of 6
days (range 4–28 days) in 31 cycles (12.4%) in 21 patients (43.8%),
mainly because of febrile neutropenia/infection with neutropenia
(seven cycles). Fourteen cycles were delayed due to reasons
unrelated to disease or treatment, including pending imaging
studies to evaluate response or the patient’s request. Dose
reduction was required in 126 (52.4%) cycles in 26 patients
(54.2%), primarily due to diarrhoea (17 patients (35.4%)) and
febrile neutropenia/infection with neutropenia (11 (22.9%)). The
relative dose intensities of docetaxel and irinotecan were 84.0%
(16.7mgm
 2 per week) and 79.3% (37.0mgm
 2 per week),
respectively.
Of the 48 eligible patients, 35 (72.9%) were discontinued due to
disease progression, 2 (4.2%) due to cerebral infarction, 1 (2.1%)
each for recurrent grade 3 diarrhoea, pulmonary embolism, gastric
tumour bleeding and death. During the study, seven patients
(14.6%) withdrew their consent because of grade 1 or 2 fatigue
(n¼4) and other reasons, including referral to other hospital
(n¼1) and economic problem (n¼2).
Toxicity
Forty-seven patients were assessable for toxicity. Table 3 sum-
marizes chemotherapy toxicities per patient. The most common
haematological toxicity was neutropenia, which occurred at grade
3/4 intensity in 27 patients (57.4%). Febrile neutropenia occurred
in seven patients (14.9%) and infection with grade 3/4 neutropenia
in four patients (8.5%). All of these patients were successfully
treated with antibiotics and G-CSF. Grade 3/4 thrombocytopenia
and anaemia occurred in one (2.1%) and seven (14.9%) patients,
respectively.
Nonhaematological toxicities were mild to moderate and
manageable. The most common grade 3/4 nonhaematological
toxicity was diarrhoea (19.1%), followed by infection without
neutropenia (10.6%), nausea (8.5%), stomatitis (6.4%), anorexia
Table 2 Response to chemotherapy of 46 evaluable patients
Response Number of patients (%)
Complete response 0 (0)
Partial response 21 (45.7)
Stable disease 15 (32.6)
Progressive disease 10 (21.7)
Overall response rate (%)
a 45.7
95% CI (%) 31.3–60.1
aOverall response¼complete response+partial response. CI¼confidence interval.
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Figure 1 Time to progression for all eligible patients.
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Figure 2 Overall survival for all eligible patients.
Table 3 Toxicity of chemotherapy per patient (n¼47)
NCI-CTC Grade (%)
Toxicity 1 2 3 4
Haematological
Leukopenia 5 (10.6) 11 (23.4) 16 (34.0) 3 (6.4)
Neutropenia 2 (4.3) 5 (10.6) 16 (34.0) 11 (23.4)
Febrile neutropenia — — 7 (14.9) 0 (0)
Thombocytopenia 0 (0) 0 (0) 1 (2.1) 0 (0)
Anaemia 11 (23.4) 27 (57.4) 7 (14.9) 0 (0)
Nonhaematological
Stomatitis 14 (29.8) 8 (17.0) 3 (6.4) 0 (0)
Anorexia 21 (44.7) 25 (53.2) 2 (4.3) 0 (0)
Nausea 28 (59.6) 14 (29.8) 4 (8.5) —
Vomiting 12 (25.5) 21 (44.7) 1 (2.1) 0 (0)
Diarrhea 17 (36.2) 11 (23.4) 7 (14.9) 2 (4.3)
Constipation 17 (36.2) 3 (6.4) 0 (0) 0 (0)
Fatigue 26 (55.3) 14 (29.8) 1 (2.1) 0 (0)
Tearing 4 (8.5) 0 (0) 0 (0) —
Myalgia 1 (2.1) 1 (2.1) 0 (0) 0 (0)
Alopecia 21 (44.7) 23 (48.9) — —
Fluid retention 8 (17.0) 6 (12.8) 0 (0)
Peripheral neuropathy 20 (42.6) 1 (2.1) 0 (0) 0 (0)
Abnormal liver function 12 (25.5) 4 (8.5) 0 (0) 0 (0)
Pneumonitis 0 (0) 1 (2.1) 0 (0) 1 (2.1)
Infection
With neutropenia — — 3 (6.4) 1 (2.1)
Without neutropenia 0 (0) 0 (0) 5 (10.6) 0 (0)
NCI-CTC¼National Cancer Institute Common Toxicity Criteria.
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pneumonitis (2.1%). There was one (2.1%) possible treatment-
related death; this patient died at home of unknown causes 5 days
after the last dose of chemotherapy in a cycle.
Second-line chemotherapy
During the follow-up period, 27 (56.3%). of the 48 eligible patients
received second-line chemotherapy, mostly containing cisplatin.
Of the 27 patients, 15 received FP, six received capecitabine/
cisplatin, three received oxaliplatin/5-FU/leucovorin and three
received other regimens. Of the efficacy-evaluable 23 patients,
three (13.0%) achieved PR, six (26.1%) had SD and 14 (60.9%)
showed progression. The median TTP of second-line chemo-
therapy was 2.4 months (95% CI 1.7–3.1 months).
DISCUSSION
We have shown here that weekly docetaxel in combination with
weekly irinotecan is an active first-line chemotherapy regimen for
MGC. The overall response rate of 45.7%, median TTP of 4.5
months and OS of 8.2 months were comparable with previously
published regimens, most of which are cisplatin-based. (Roth et al,
2000; Kettner et al, 2001; Ridwelski et al, 2001; Ajani et al, 2002;
Lim et al, 2003; Pozzo et al, 2004; Ajani et al, 2005; Dank et al,
2005; Moiseyenko et al, 2005).
The administration of docetaxel-irinotecan every 3 weeks was
performed as first-line chemotherapy for this disease with
response rate of 37.5% (Hawkins et al, 2003). Although our weekly
regimen showed lower incidence of grade 3/4 toxicities than tri-
weekly regimen (neutropenia 57.4 vs 85.4%, febrile neutropenia/
infection with neutropenia 23.4 vs 41.4%, and diarrhoea 19.1 vs
42.9%), its toxicity should be generally considered significant.
Cisplatin-containing regimens have shown grade 3/4 neutropenia,
febrile neutropenia/infection with neutropenia and diarrhoea in
27–87%, 2–30% and 5–22% of patients, according to the
published literature. On the other hand, compared with cispla-
tin-containing regimens, docetaxel/irinotecan combination was
associated with a lower incidence of grade 2 or higher
neurotoxicity (2.1 vs 2.0-30.8%) and all grade ototoxicity (0 vs
52.7%) (Roth et al, 2000; Kettner et al, 2001; Ridwelski et al, 2001;
Ajani et al, 2002; Lim et al, 2003; Pozzo et al, 2004; Ajani et al,
2005; Dank et al, 2005; Moiseyenko et al, 2005). In addition, this
regimen did not resulted in any grade of nephrotoxicity.
Notably, this weekly regimen involved frequent dose reduction,
especially of irinotecan, primarily due to diarrhoea, which
occurred mainly in the first 1–3 cycles of therapy and was hardly
repeated subsequently after a dose reduction. So, we would
propose that the recommended irinotecan dose of this weekly
regimen be lowered from 70 to 60mgm
 2, and that this regimen
should be given only to patients with good performance status
without any comorbidities. Yet, this weekly regimen allowed us to
better modify subsequent drug dose and better manage drug
toxicity with at least comparable therapeutic efficacy, compared
with tri-weekly regimen. Taken together, we conclude that weekly
docetaxel and irinotecan combination chemotherapy is a promis-
ing outpatient regimen in MGC, with appropriate dose modifica-
tions.
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